Fig. 4From: Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept studyChange in A plasma Aβ42/40 ratio and B p-tau181 by treatment group in study 201 core based on standardized valueBack to article page